Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingAnnualDividendRate,trailingPE,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,trailingAnnualDividendYield,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,DNPUF,20672000000.0,397295008,25571000000,,-1874000000,67608000000,-14038000000,43203000000,88340000000,2683000000,2683000000,16883000000,,,,,19205000000,121190000000,118507000000,32850000000,-4557000000,,-21079000000,-14038000000,383406000000.0,15855000000.0,659949000000.0,580570000000.0,203549000000.0,1308127000000.0,22400000000.0,8342000000.0,508677000000.0,117943000000.0,176492000000.0,33638000000.0,30433000000.0,193698000000.0,278147000000.0,20191000000.0,9960000000.0,34317000000.0,64966000000.0,459795000000.0,193035000000.0,29480000000.0,136060000000.0,263859000000.0,92215000000.0,64638000000.0,2158000000,5266000000,-26687000000,-21908000000,-38801000000,-8324000000,-26136000000,11631000000,27721000000,8053000000,58000000,-10000000,-1879000000,17442000000,-16883000000,21201000000,-1635000000,181648000000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,16.45 - 16.45,16.45,finmb_876269,Other OTC,"Sumitomo Dainippon Pharma Co., Ltd.",JPY,64,0,4.000001,0.32128522,12.45 - 20.2,-3.75,-0.18564355,12.45,20.2,28.0,12.86161,-14400000,False,False,USD,REGULAR,1.7021276,1.279,1461.311,18.429167,-1.979166,-0.10739314,17.990942,-1.5409412,-0.08565095,6811715072,0.011257015,15,America/New_York,EDT,SUMITOMO DAINIPPON PHARMA CO LT,16.45,1628265098,0.0,16.45,16.45,16.45,1,0,PNK,2,us_market,0.44,,,20.2,12.45,18.43,17.99,64,,397.3M,,173.82M,59.25%,20.08%,,,,,,0.26,1.30%,28.00,170.21%,,16.60%,,"Sep 28, 2021",,,"Mar 30, 2021","Mar 30, 2021",10.90%,17.49%,4.40%,5.75%,515.95B,1298.66,-3.60%,378.31B,112.89B,56.22B,1.28,,223.18B,561.74,273.82B,42.24,1.65,1461.31,135.6B,108.33B,Value,541-0045,Healthcare,1,1,"Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.",Osaka,81 6 6203 5321,4,1622505600,2,Japan,http://www.ds-pharma.com,86400,2,6-8 Doshomachi 2-chome,81 6 6202 6028,Drug Manufacturersâ€”Specialty & Generic,Chuo-ku
t-1,DNPUF,-16329000000.0,397295008,22464000000,,36071000000,91406000000,32960000000,52846000000,99163000000,39997000000,39997000000,-16144000000,-4318000000.0,,,,8502000000,133264000000,93267000000,34101000000,-3926000000,,27569000000,32960000000,398495000000.0,16432000000.0,670267000000.0,547164000000.0,178395000000.0,1308837000000.0,22400000000.0,7860000000.0,516243000000.0,142539000000.0,164998000000.0,-7911000000.0,39985000000.0,219834000000.0,263168000000.0,39985000000.0,,-7233000000.0,62756000000.0,464715000000.0,177888000000.0,5251000000.0,148861000000.0,264560000000.0,82909000000.0,54813000000.0,-1501000000,2212000000,16190000000,-2751000000,-8621000000,86895000000,85124000000,-4256000000,81811000000,5113000000,-11000000,-5550000000,-3008000000,-10663000000,-320000000,-26307000000,-1448000000,201547000000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,16.45 - 16.45,16.45,finmb_876269,Other OTC,"Sumitomo Dainippon Pharma Co., Ltd.",JPY,64,0,4.000001,0.32128522,12.45 - 20.2,-3.75,-0.18564355,12.45,20.2,28.0,12.86161,-14400000,False,False,USD,REGULAR,1.7021276,1.279,1461.311,18.429167,-1.979166,-0.10739314,17.990942,-1.5409412,-0.08565095,6811715072,0.011257015,15,America/New_York,EDT,SUMITOMO DAINIPPON PHARMA CO LT,16.45,1628265098,0.0,16.45,16.45,16.45,1,0,PNK,2,us_market,0.44,,,20.2,12.45,18.43,17.99,64,,397.3M,,173.82M,59.25%,20.08%,,,,,,0.26,1.30%,28.00,170.21%,,16.60%,,"Sep 28, 2021",,,"Mar 30, 2021","Mar 30, 2021",10.90%,17.49%,4.40%,5.75%,515.95B,1298.66,-3.60%,378.31B,112.89B,56.22B,1.28,,223.18B,561.74,273.82B,42.24,1.65,1461.31,135.6B,108.33B,Value,541-0045,Healthcare,1,1,"Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.",Osaka,81 6 6203 5321,4,1622505600,2,Japan,http://www.ds-pharma.com,86400,2,6-8 Doshomachi 2-chome,81 6 6202 6028,Drug Manufacturersâ€”Specialty & Generic,Chuo-ku
t-2,DNPUF,-28925000000.0,397295008,23462000000,,21675000000,92524000000,19038000000,45161000000,92917000000,24268000000,24268000000,26000000,-2679000000.0,,,,6902000000,127641000000,103373000000,34724000000,-2593000000,,14773000000,19038000000,408059000000.0,16641000000.0,602491000000.0,543473000000.0,155472000000.0,1238488000000.0,22400000000.0,11892000000.0,488845000000.0,96541000000.0,164339000000.0,15587000000.0,31984000000.0,134710000000.0,365477000000.0,31984000000.0,,16264000000.0,63733000000.0,377422000000.0,192951000000.0,3841000000.0,145156000000.0,140473000000.0,81823000000.0,53045000000.0,773000000,92000000,-2161000000,198000000,-459000000,11698000000,21332000000,-1600000000,25552000000,5099000000,20000000,-74000000,-4484000000,-3102000000,-583000000,1476000000,-1902000000,11945000000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,16.45 - 16.45,16.45,finmb_876269,Other OTC,"Sumitomo Dainippon Pharma Co., Ltd.",JPY,64,0,4.000001,0.32128522,12.45 - 20.2,-3.75,-0.18564355,12.45,20.2,28.0,12.86161,-14400000,False,False,USD,REGULAR,1.7021276,1.279,1461.311,18.429167,-1.979166,-0.10739314,17.990942,-1.5409412,-0.08565095,6811715072,0.011257015,15,America/New_York,EDT,SUMITOMO DAINIPPON PHARMA CO LT,16.45,1628265098,0.0,16.45,16.45,16.45,1,0,PNK,2,us_market,0.44,,,20.2,12.45,18.43,17.99,64,,397.3M,,173.82M,59.25%,20.08%,,,,,,0.26,1.30%,28.00,170.21%,,16.60%,,"Sep 28, 2021",,,"Mar 30, 2021","Mar 30, 2021",10.90%,17.49%,4.40%,5.75%,515.95B,1298.66,-3.60%,378.31B,112.89B,56.22B,1.28,,223.18B,561.74,273.82B,42.24,1.65,1461.31,135.6B,108.33B,Value,541-0045,Healthcare,1,1,"Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.",Osaka,81 6 6203 5321,4,1622505600,2,Japan,http://www.ds-pharma.com,86400,2,6-8 Doshomachi 2-chome,81 6 6202 6028,Drug Manufacturersâ€”Specialty & Generic,Chuo-ku
t-3,DNPUF,-42618000000.0,397295008,25744000000,,21979000000,95758000000,18259000000,49012000000,97887000000,23271000000,23271000000,-140000000,-1937000000.0,,,,6413000000,133857000000,110586000000,35970000000,-1292000000,,15566000000,18259000000,416318000000.0,17546000000.0,599394000000.0,541036000000.0,150006000000.0,1236188000000.0,22400000000.0,12524000000.0,470027000000.0,98128000000.0,167336000000.0,31063000000.0,28980000000.0,113378000000.0,476986000000.0,28980000000.0,,31740000000.0,64518000000.0,353479000000.0,205557000000.0,3797000000.0,144802000000.0,24280000000.0,78978000000.0,54020000000.0,-2655000000,-7734000000,21533000000,-740000000,-9334000000,15316000000,11670000000,-1046000000,517000000,4408000000,158000000,-5486000000,-668000000,-3492000000,-3108000000,-22879000000,-1063000000,-123507000000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,16.45 - 16.45,16.45,finmb_876269,Other OTC,"Sumitomo Dainippon Pharma Co., Ltd.",JPY,64,0,4.000001,0.32128522,12.45 - 20.2,-3.75,-0.18564355,12.45,20.2,28.0,12.86161,-14400000,False,False,USD,REGULAR,1.7021276,1.279,1461.311,18.429167,-1.979166,-0.10739314,17.990942,-1.5409412,-0.08565095,6811715072,0.011257015,15,America/New_York,EDT,SUMITOMO DAINIPPON PHARMA CO LT,16.45,1628265098,0.0,16.45,16.45,16.45,1,0,PNK,2,us_market,0.44,,,20.2,12.45,18.43,17.99,64,,397.3M,,173.82M,59.25%,20.08%,,,,,,0.26,1.30%,28.00,170.21%,,16.60%,,"Sep 28, 2021",,,"Mar 30, 2021","Mar 30, 2021",10.90%,17.49%,4.40%,5.75%,515.95B,1298.66,-3.60%,378.31B,112.89B,56.22B,1.28,,223.18B,561.74,273.82B,42.24,1.65,1461.31,135.6B,108.33B,Value,541-0045,Healthcare,1,1,"Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.",Osaka,81 6 6203 5321,4,1622505600,2,Japan,http://www.ds-pharma.com,86400,2,6-8 Doshomachi 2-chome,81 6 6202 6028,Drug Manufacturersâ€”Specialty & Generic,Chuo-ku
